VOL 36 No. 2

Recent developments in the clinical capabilities of magnetic resonance spectroscopy (MRS) have provided researchers with considerable insight into potential neurochemical alterations associated with the pathology and treatment of affective disorders. This review focuses on the...

The serum anticholinergic activity (SAA) assay was originally designed to quantify the anticholinergic burden of drug exposure. The same assay has been used to measure the anticholinergic activity of standard drug solutions. There are limitations...

Diabetes is a common endocrine disorder increasingly encountered in patients requiring treatment with psychoactive drugs. The pharmacotherapy options for diabetes have expanded in recent years and now include 14 oral hypoglycemic drugs from five pharmacologic...

Tiagabine is currently approved by the Food and Drug Administration for use in treating certain forms of epilepsy. Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic...

Although there have been previously published algorithms for the treatment of depression, few have been rigorously studied in terms of outcome. We present the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED) approach, developed by...

Although patients with borderline personality disorder (BPD) are commonly seen in psychiatric practice, there has been far less biological research in BPD than in other psychiatric disorders. This article reviews the neurobiological research that has...

The eating disorders anorexia nervosa (AN) and bulimia nervosa (BN) are multifactorial syndromes of unknown origin which occur typically in female adolescents or young women. Nowadays, AN and BN are most often triggered by dietary...

The omnipresent worry and anxiety that are characteristic of generalized anxiety disorder (GAD) significantly reduce social and occupational functioning. Yet many clinical investigations of GAD fail to evaluate treatment-related changes in function. As a consequence,...